GRAIL Q2 2026 earnings: Galleri growth contrasts with a wider operating loss

GRAIL (Nasdaq: GRAL) reported Q2 2026 revenue of $44.7 million, up 26% from $35.5 million, while diluted net loss per share narrowed to $2.56 from $3.18. Galleri test volume increased 35% to more than 61,000 and Galleri revenue rose 24%, but the operating loss widened as sales, marketing and administrative expenses increased. The quarter ended June 30, 2026.

Core financial results

Screening revenue generated approximately 95% of quarterly revenue and about 90% of the year-over-year revenue increase. GRAIL also reduced its GAAP gross loss, but higher operating expenses prevented that improvement from reaching operating income.

GAAP gross margin was approximately negative 28%, compared with negative 50% a year earlier. On a non-GAAP basis, adjusted gross margin was approximately 48%, up from 45%; the reconciliation excludes $33.5 million of intangible asset amortization and $0.6 million of stock-based compensation from cost of revenue.

Galleri drove most of the revenue growth

Galleri screening revenue increased to $42.6 million from $34.4 million, accounting for most of the company’s $9.1 million increase in total revenue. Test volume grew faster than revenue—35% versus 24%—meaning reported Galleri revenue did not rise at the same rate as testing activity.

Development services revenue increased to $2.0 million from $1.2 million, an approximately 76% gain, but remained less than 5% of total revenue. For the first half of 2026, reported separately from the quarterly figures, Galleri revenue increased 30% to $82.5 million as volume rose 42% to more than 117,000 tests.

Revenue growth did not prevent a wider operating loss

The principal pressure came from sales and marketing and general and administrative expenses. GRAIL said it completed an expansion of its field sales and medical teams, consistent with the increase in commercial spending.

Total costs and operating expenses increased by $24.1 million, more than the $9.1 million revenue gain. That caused the operating loss to widen by $14.9 million.

The narrower net loss therefore does not indicate an improvement in operating profitability. Loss before income taxes increased to $166.7 million from $152.9 million, but the reported income tax benefit rose to $56.5 million from $38.9 million. Adjusted EBITDA, which excludes the tax benefit and several non-cash items, consequently moved in the opposite direction from GAAP net loss.

Cash position and Samsung financing

Cash, cash equivalents and short-term marketable securities totaled $861.6 million at June 30, down approximately $42.8 million from $904.4 million at the end of 2025. Most of the June balance was held in short-term securities rather than cash.

GRAIL completed a $110 million common-stock financing with Samsung C&T and Samsung Electronics during June. Common shares outstanding increased to 44.7 million from 40.3 million at the end of 2025, an approximately 11% increase. The companies also intend to collaborate on potential Galleri commercialization in South Korea and, subject to regulatory approvals and other conditions, additional Asian markets.

Clinical evidence supports detection claims but leaves endpoint uncertainty

The NHS-Galleri study did not show a statistically significant decrease in combined Stage III and IV cancers. However, GRAIL reported that Galleri reduced Stage IV diagnoses among 12 prespecified aggressive cancers by 22% and 26% in the second and third screening rounds, respectively. Adding Galleri to standard screening also increased cancer detection fourfold and raised the number of Stage I and II screen-detected cancers by 128%.

PATHFINDER 2 provided additional evidence on detection and diagnostic follow-up. Approximately 60% of cancers were identified through screening after Galleri was added, 53% of newly detected cancers were Stage I or II, and the test identified the cancer signal origin correctly more than 90% of the time.

GRAIL submitted its Galleri premarket approval application earlier in 2026 and anticipates an FDA advisory committee meeting in the fall. The application uses data from 25,000 consented PATHFINDER 2 participants and the first screening round of the 140,000-participant NHS-Galleri trial. Galleri had not been cleared or approved by the FDA as of the earnings release.

Recent insider transactions

The supplied insider data reports 13 purchases totaling 200,083 shares and nine sales totaling 250,093 shares over the preceding six months. That represents net sales of 50,010 shares, or 2.2% of the reported 2.24 million insider shares held.

The latest 10 reported transactions consisted of nine direct stock awards and one direct sale. The figures below are the source’s reported transaction values, not share quantities.

Because most of these entries were compensation-related awards, they should not be interpreted as discretionary open-market purchases.

Risks investors need to watch

• Regulatory uncertainty: Galleri remains unapproved by the FDA, and the timing and outcome of the anticipated advisory committee review are uncertain.
• Mixed clinical evidence: NHS-Galleri produced favorable detection and Stage IV subgroup findings but did not significantly reduce the combined Stage III and IV endpoint.
• Persistent operating losses: Higher commercial and administrative spending caused operating and adjusted EBITDA losses to widen despite revenue growth and better gross profitability.
• Volume and revenue divergence: Galleri test volume grew faster than Galleri revenue, making the relationship between testing activity and monetization an important metric to monitor.
• Share dilution: The Samsung equity financing strengthened available capital, while shares outstanding increased approximately 11% from year-end 2025.

Summary

GRAIL’s second-quarter growth remained concentrated in Galleri, with higher test volume driving most of the revenue increase and adjusted gross profitability improving. The benefit was outweighed at the operating level by greater sales, marketing and administrative spending, while the modest improvement in GAAP net loss depended on a larger tax benefit. The next major operating and regulatory checkpoints are whether Galleri revenue can keep pace with test growth, whether expenses become more aligned with revenue, and how the FDA review progresses.